After developing treatments for rare tumors, SpringWorks Therapeutics is taking a buyout offer from Germany-based Merck KGaA.

Rowley Law PLLC is investigating potential securities law violations by SpringWorks Therapeutics, Inc. and its board of directors concerning the proposed acquisition of the company by Merck KGaA.